


Polyplus acquires e-Zyvec

01 February 2022 | News

To expand expertise in plasmid DNA vector engineering



Polyplus, a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial grade, announced the acquisition of e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors for gene-therapy, bio-manufacturing and research. Financial details were not disclosed.

"When we launched e-Zyvec five years ago, the idea was to bring a different type of genetic engineering service to the market, leveraging today's digital technology," said Sylvain Julien, President and Co-Founder, e-Zyvec.

"Joining the Polyplus team is an organic transition for our team, enabling us to expand this technology across the global market. Our full team will carry forward in their current roles, delivering a layer of expertise and human capital that is invaluable in today's market," said Carine Morel, MD and Co-Founder, e-Zyvec.

"We will continue to build out the existing portfolio, which is strong on its own, by adding complementary activities that make us a more effective and comprehensive partner to our customers, with a focus on expanding process economics optimisation efforts for cell and gene therapy developers and manufacturers," Mario Philips, CEO, Polyplus commented.